research Drug-induced vitiligo: a real-world pharmacovigilance analysis of the FAERS database
Certain drugs may cause vitiligo, so patients should be monitored.
Search
for
Sort by
Research
390-420 / 1000+ results 
research The nocebo effect: A clinicians guide
Negative expectations can cause adverse effects in patients even without active treatment, and managing this nocebo effect involves better communication and patient-clinician relationships.
research Effect of Fexofenadine as an Adjunct to DPCP in Non-Atopic Patients with Alopecia Areata: A Randomized Clinical Trial
Fexofenadine reduces discomfort but doesn't significantly improve hair regrowth in Alopecia Areata treatment.
research Detection of NUDT15 R139C variants and azathioprine utilization in patients with dermatologic conditions
research Vitamins
Taking too much vitamin A can cause health problems like bone pain and hair loss.
research Fabrication of polyvinyl pyrrolidone-K90/Eudragit RL100-based dissolving microneedle patches loaded with alpha-arbutin and resveratrol for skin depigmentation
Microneedle patches with alpha-arbutin and resveratrol can effectively reduce skin pigmentation without irritation.
research Association Between 5-Alpha Reductase Inhibitor Use and The Risk of Depression: A Meta-Analysis.
Using 5-alpha reductase inhibitors may increase the risk of mild depression.
research Safety profile of CAP7.1 obtained during Phase I Trial in adult patients with refractory malignancies
CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.
research A IMPORTÂNCIA DA ATENÇÃO FARMACÊUTICA DIANTE DO AUMENTO DA PRESCRIÇÃO E USO INDISCRIMINADO DE ANSIOLÍTICOS COM FOCO NOS BENZODIAZEPÍNICOS E NA PASSIFLORA INCARNATA L.
Pharmacists play a key role in managing the use of anxiety medications and ensuring patients use them correctly.
research The role of Paraoxonase 1 in Alopecia Areata, a Marker and a Severity Index
Lower Paraoxonase 1 levels in alopecia areata patients suggest antioxidant treatment might help.
research A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata
Apremilast was not effective in treating moderate-to-severe alopecia areata.
research Clinical Management of Cutaneous Adverse Events in Patients on Chemotherapy: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
Proper skin toxicity management in chemotherapy is key to continuing treatment and keeping patient quality of life high.
research Differential association between cumulative dose of 5α-reductase inhibitors and mortality
Higher doses of 5α-reductase inhibitors may lower mortality risk, but low doses increase it.
research The management of EGFR inhibitor adverse events: a case series and treatment paradigm
Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.
research Comparative Study between The Efficacy and Safety of Topical Immune Therapy with Diphenylcyclopropenone versus Anthralin in The Treatment of Resistant Alopecia Areata
Diphenylcyclopropenone (DPCP) is more effective than anthralin for treating resistant alopecia areata.
research Faculty Opinions recommendation of Solitary fixed drug eruption caused by finasteride.
Finasteride can cause skin reactions, so dermatologists should be aware.
research Using risk analysis to guide changes to compounding formulae
Risk analysis is important for safely adjusting pharmaceutical formulas while maintaining their quality and effectiveness.
research Reminder of finasteride-related psychiatric AEs and sexual dysfunction
research Iododerma in pregnancy secondary to iodinated multivitamins
A man developed an allergic skin reaction to a rosacea treatment and improved after stopping the medication and receiving allergy-specific care.
research Allergic contact dermatitis to topical brimonidine
A man developed an allergic skin reaction after using brimonidine for rosacea.
research 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
research A10.09 Safety data of four treatment regimens in early rheumatoid arthritis patients
All four treatments for early rheumatoid arthritis had similar and mostly mild side effects.
research Digoxin-induced anemia among patients with atrial fibrillation and heart failure: clinical data analysis and drug-gene interaction network
Digoxin is linked to a higher risk of anemia in patients with atrial fibrillation and heart failure.
research Maculopapular rash upon antibiotic therapy in a patient with rheumatoid arthritis
Methotrexate caused a rare skin rash in a rheumatoid arthritis patient, which resolved after stopping the drug.
research Severity grading of dermatological emergencies based on comorbidities and systemic involvement: An observational study
Skin emergency severity rises with other health issues and affects multiple organs; a new grading system can improve patient care.
research Evaluation of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, mean platelet volume, CRP and ESR with disease severity in patients with alopecia areata
Higher MPV and CRP levels may indicate more severe alopecia areata.
research Effects of prasugrel versus clopidogrel on coronary microvascular function in patients undergoing elective percutaneous coronary intervention: A randomized double-blind study
Prasugrel is better than clopidogrel at preventing heart damage and improving blood flow in small heart vessels during heart artery procedures.
research [Adverse drug reactions on hair].
Some drugs can cause hair loss, increase hair growth, or change hair color, but stopping the drug usually reverses these effects.
research Characteristics and predictive values of super-responders in alopecia areata under tofacitinib treatment: A single-center retrospective study
Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.
research Results of stage I in a phase II randomized bilateral comparison of bexarotene 1% topical gel in alopecia areata
Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.